Structure-Based QSAR Modeling of RET Kinase Inhibitors from 49 Different 5,6-Fused Bicyclic Heteroaromatic Cores to Patent-Driven Validation

基于结构的 RET 激酶抑制剂 QSAR 模型研究:从 49 种不同的 5,6-稠合双环杂芳环核心结构到专利驱动的验证

阅读:1

Abstract

RET receptor tyrosine kinase is crucial for nerve and tissue development but can be an important oncogenic driver. This study focuses on exploring the design principles of potent RET inhibitors through molecular docking and 3D-QSAR modeling of 5,6-fused bicyclic heteroaromatic derivatives. First of all, RET inhibitors of 49 different bicyclic substructures were collected from five different data sources and selected through molecular docking simulations. QSAR models were built from the 3399 conformers of 952 RET inhibitors using the partial least-squares method and statistically evaluated. The optimal QSAR model exhibited high predictive performance, with R (2) (of training data) and Q (2) (of test data) values of 0.801 and 0.794, respectively, effectively predicting known inhibitors. The optimal model was doubly verified by patent-filed RET inhibitors as the out-of-set data to demonstrate acceptable residual analysis results. Moreover, feature importance analysis of the QSAR model outlined the impact of substituent characteristics on the inhibitory activity within the 5,6-fused bicyclic heteroaromatic core structures. Furthermore, the relationship between structure and inhibitory activity was successfully applied to the RET screening of known clinical and nonclinical kinase inhibitors to afford accurate off-target prediction.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。